Brian Leyland-Jones, MBBS, PhD, director, Edith Sanford Breast Cancer Research, discusses the development of breast cancer risk assessment tools.
Brian Leyland-Jones, MBBS, PhD
Advertisement
Articles by Brian Leyland-Jones, MBBS, PhD
Brian Leyland-Jones, MBBS, PhD, discusses results from the phase III HERA trial that compared 2 years of adjuvant trastuzumab to the standard 1 year in HER2-postive early-stage breast cancer.
Dr. Brian Leyland-Jones from Winship Cancer Institute Discusses Genome Sequencing
Advertisement
Latest Updated Articles
Dr. Leyland-Jones Discusses Genome SequencingPublished: February 20th 2012 | Updated:
Dr. Leyland-Jones on Breast Cancer Risk Assessment ToolsPublished: March 3rd 2014 | Updated:
Dr. Leyland-Jones Discusses the Phase III HERA TrialPublished: December 7th 2012 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
3
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
4
Northwestern Medicine Surgeons Develop a Total Artificial Lung System to Keep a Patient Alive for 48 Hours After Removing Both Lungs, Enabling a Double-Lung Transplant
5